MGC Pharmaceuticals Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MXC.L research report →
Companymgcpharma.com.au
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company's principal product candidates include CimetrA, which is in phase III clinical trial for early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for symptomatic relief of Dementia. It has research and development agreement with Royal Melbourne Institute of Technology and the University of Notre Dame; and collaboration agreement with the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre.
- CEO
- Roby Reuven Zomer
- IPO
- 2021
- HQ
- West Perth, WA, AU
Price Chart
Valuation
- Market Cap
- $9.30M
- P/E
- -0.06
- P/S
- 5.44
- P/B
- -0.17
- EV/EBITDA
- -1.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 37.96%
- Op Margin
- -457.29%
- Net Margin
- -614.64%
- ROE
- 2660.08%
- ROIC
- -257.29%
Growth & Income
- Revenue
- $3.39M · -28.40%
- Net Income
- $-20,824,000 · -2.34%
- EPS
- $-7.10 · 10.13%
- Op Income
- $-15,234,000
- FCF YoY
- 18.02%
Performance & Tape
- 52W High
- $600.00
- 52W Low
- $13.10
- 50D MA
- $20.06
- 200D MA
- $78.63
- Beta
- 1.03
- Avg Volume
- 27.43K
Get TickerSpark's AI analysis on MXC.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MXC.L Coverage
We haven't published any research on MXC.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MXC.L Report →